Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Gynecologic 1Endocrine 1Breast 1

Conditions

Ovarian Neoplasms 96Carcinoma, Ovarian Epithelial 31Fallopian Tube Neoplasms 28Breast Neoplasms 25Carcinoma, Non-Small-Cell Lung 21Melanoma 20Uterine Cervical Neoplasms 16Pancreatic Neoplasms 14Neoplasm Metastasis 13Colorectal Neoplasms 13Stomach Neoplasms 11Triple Negative Breast Neoplasms 10Carcinoma, Hepatocellular 10Sarcoma 9Lung Neoplasms 9Head and Neck Neoplasms 9Recurrence 8Neoplasms 8Anus Neoplasms 8Multiple Myeloma 7Esophageal Neoplasms 7Sarcoma, Synovial 6Neuroblastoma 6Carcinoma, Renal Cell 6Vaginal Neoplasms 5Urinary Bladder Neoplasms 5Testicular Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Penile Neoplasms 5Lymphoma, Non-Hodgkin 5

Interventions

aldesleukin 2Trastuzumab 2zimberelimab 1trametinib 1tipifarnib 1sargramostim 1fludarabine 1dabrafenib 1cobimetinib 1Vemurafenib 1Nivolumab 1Ipilimumab 1Interleukin-12 Subunit p35 1Interleukin-12 1Cyclophosphamide 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Carcinoma, Anaplastic × Cyclophosphamide × Gynecologic × Clear all
NCT03449108 2026-05-22

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡